Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas by Pihan, German A. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2003-03-22 
Centrosome abnormalities and chromosome instability occur 
together in pre-invasive carcinomas 
German A. Pihan 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Medical Molecular Biology Commons, Oncology Commons, and the Pathology Commons 
Repository Citation 
Pihan GA, Wallace J, Zhou Y, Doxsey SJ. (2003). Centrosome abnormalities and chromosome instability 
occur together in pre-invasive carcinomas. Open Access Articles. Retrieved from 
https://escholarship.umassmed.edu/oapubs/358 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
[CANCER RESEARCH 63, 1398–1404, March 15, 2003]
Centrosome Abnormalities and Chromosome Instability Occur Together in
Pre-invasive Carcinomas1
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Departments of Pathology [G. A. P., J. W., Y. Z.] and Molecular Medicine [S. J. D.], University of Massachusetts Medical School, Worcester, Massachusetts 01605
ABSTRACT
Centrosomes play critical roles in processes that ensure proper segre-
gation of chromosomes and maintain the genetic stability of human cells.
They contribute to mitotic spindle organization and regulate aspects of
cytokinesis and cell cycle progression. We and others have shown that
centrosomes are abnormal in most aggressive carcinomas. Moreover,
centrosome defects have been implicated in chromosome instability and
loss of cell cycle control in invasive carcinoma. Others have suggested that
centrosome defects only occur late in tumorigenesis and may not contrib-
ute to early steps of tumor development. To address this issue, we exam-
ined pre-invasive human carcinoma in situ lesions for centrosome defects
and chromosome instability. We found that a significant fraction of pre-
cursor lesions to some of the most common human cancers had centro-
some defects, including in situ carcinomas of the uterine cervix, prostate,
and female breast. Moreover, centrosome defects occurred together with
mitotic spindle defects, chromosome instability, and high cytologic grade.
Because most pre-invasive lesions are not uniformly mutant for p53, the
development of centrosome defects does not appear to require abrogation
of p53 function. Our findings demonstrate that centrosome defects occur
concurrently with chromosome instability and cytologic changes in the
earliest identifiable step in human cancer. Our results suggest that cen-
trosome defects may contribute to the earliest stages of cancer develop-
ment through the generation of chromosome instability. This, together
with ongoing structural changes in chromosomes, could accelerate accu-
mulation of alleles carrying pro-oncogenic mutations and loss of alleles
containing wild-type tumor suppressor genes and thus accelerate the
genomic changes characteristic of carcinoma, the most prevalent human
cancer.
INTRODUCTION
CIN3 is the most common form of genetic instability in human
cancer and thought to be caused by continuous chromosome misseg-
regation during mitosis (1, 2). Together with structural chromosome
changes caused by chromosome breakage and misrepair, CIN is
thought to be important to promote the Darwinian genomic evolution
characteristic of cancer, whereby proto-oncogene mutations accumu-
late, and normal alleles of mutated tumor suppressor genes are lost
(2–4). In fact, loss of heterozygosity in cancer primarily affects whole
chromosomes or large chromosomal domains, suggesting that it re-
sults from gains or losses of entire normal or rearranged chromosomes
(5). CIN is thought to facilitate the inexorable evolution of cancers
toward cellular states that support tumor cell growth, dissemination,
and resistance to therapy (1–3, 6, 7). A common element in the chain
of events associated with loss of fidelity in chromosome segregation
is centrosome dysfunction (for review, see Refs. 7–12).
Centrosomes are the primary microtubule-organizing centers in
animal cells. They contribute to the organization of microtubule
spindles in mitosis and appear to control progression through cytoki-
nesis and entry into S phase (9, 13–15). Our laboratory and another
first detected centrosome defects in aggressive carcinomas of multiple
origins (2, 16). Several subsequent studies confirmed these observa-
tions and extended them to other tumor types and animal models
(17–22). The discovery of centrosome defects in essentially all car-
cinomas sparked interest in this organelle as a global contributor to the
development and progression of tumors that exhibit genetic instability
(2, 8–11, 23). The established role of centrosomes in organizing
mitotic spindles suggested a model in which tumor cells with multiple
centrosomes organize multipolar spindles that missegregate chromo-
somes and contribute to genetic instability. This phenomenon could
occur in diploid cells or cells that failed previously in cell division to
create polyploid cells with supernumerary centrosomes (24). Despite
the occurrence of centrosome defects in most common human cancers
and their known role in the assembly of mitotic spindles and chro-
mosome segregation, a role for centrosomes in the earliest steps of
human tumor development has not been well established.
Recent results from our laboratory have shown that centrosome
defects and genetic instability occur in some low-grade prostate
tumors, suggesting that they are present before development of ag-
gressive tumors (21). Moreover, overexpression of some centrosome-
associated proteins, including pericentrin, TACC, polo, and aurora
(21, 24–28), induces tumor-like features. Centrosome defects have
also been observed during the early stages of tumor development in a
rat mammary carcinogenesis model (29), suggesting that centrosome
defects may also occur in pre-invasive human tumors. A recent study
of invasive human carcinoma showed that centrosome abnormalities
occurred in some pre-invasive breast lesions (20). The authors ana-
lyzed seven cases of breast tissue and reported on one parameter of
centrosome defect (size) but did not examine the relationship between
centrosome defects and CIN in the pre-invasive lesions. It is important
to perform a comprehensive analysis of centrosome defects in pre-
invasive lesions for several reasons. A comparative analysis of pre-
invasive lesions from tissues with different propensities to develop
aggressive cancers may provide important information about the role
of centrosomes in the development and progression of cancer. This
type of analysis could also identify centrosome defects as a universal
diagnostic indicator of most, if not all, carcinomas. The presence of
centrosome defects in pre-invasive lesions may also provide a prog-
nostic marker for tumor development, especially in prostate cancer,
where the relationship of pre-invasive lesions to aggressive cancer is
unclear.
In this study, we analyzed 116 pre-invasive lesions from three
different human tissues (breast, cervix, and prostate). We show that
centrosome defects occur in all tissue tissues and that they coseg-
regate with other tumor-like features associated with centrosome
dysfunction, including spindle abnormalities, cytologic changes,
and CIN (2, 21).
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Immunohistochemical Staining and Analysis. Formalin-fixed, paraffin-
embedded tissue from carcinoma in situ of the uterine cervix, female breast,
and male prostate was selected from the files of the Pathology Department at
UMass Memorial Health Care. Samples were immunostained with pericentrin
antibodies as described (2, 21, 27). Standard histopathologic criteria were
applied to newly prepared H&E-stained sections to confirm the presence of
carcinoma in situ in the specimen (30). Centrosomes were considered abnor-
mal if they had a diameter greater than twice the diameter of centrosomes
present in normal epithelium within the same section, if the ratio of their
greatest and smallest diameter exceeded 2 or if there were more than two
centrosomes in 5% of the cells examined (21). -tubulin was chosen to stain
mitotic spindles in archival formalin-fixed, paraffin-embedded tissues because
it decorates spindle poles, whereas a large fraction of  and  tubulins is
cytoplasmic and obscures the spindle microtubule signal.4 Multipolar mitoses,
an obvious consequence of supernumerary centrosomes, are common in car-
cinoma cell lines with abnormal centrosomes, as we et al. (2, 22, 31, 32) have
shown previously.
CIN Analysis. Tissue sections parallel to those used for pericentrin
immunohistochemistry were used to stain centromeres of chromosome 1
and 8 (2). Briefly, after deparaffinization, sections were codenatured with
biotinylated centromeric probes specific for chromosomes 1 or 8 and
hybridized overnight at 37°C in a Hybrite oven (Vysis, Chicago, IL) in the
hybridization buffer recommended by the probe manufacturer. After ap-
propriate stringency washes, sections were placed on the automatic immu-
nostainer, and an avidin-biotin complex method/3,3-diaminobenzidine
protocol similar to the one used above for immunohistochemistry was used
to reveal the hybridized probe. Nuclei were lightly counterstained with
hematoxylin. For quantitative analysis, the number of hybridization signals
in 100 –200 nuclei from in situ carcinoma and morphologically normal
adjacent epithelium was recorded (2). Using these probes, it has been
shown that normal diploid tissue has 10 –15% cells with more than three
signals per nucleus (2, 33). In tissue sections, some nuclei are truncated,
leading to artificially increased numbers of diploid cells with apparently
less than two signals per nuclei. For this reason, we primarily computed
signal gains (greater than two) and not apparent losses. We also separately
analyzed cells with only one copy of a given chromosome. Because of
limitations imposed by truncation artifacts, we did not attempt to obtain an
absolute measure of chromosome instability in sections, as it can be done4 G. A. Pihan, unpublished observations.
Fig. 1. Centrosome defects occur in carcinoma in
situ. Photomicrographs of normal epithelium (A, C,
and E) and adjacent in situ carcinoma (B, D, and F)
immunostained with antibodies to pericentrin to vi-
sualize centrosomes. Magnifications are all the same
(1000). In normal epithelia, centrosomes are round
and uniform in size (arrowheads, A, C, and E),
whereas in carcinoma in situ, they are larger (arrow-
heads in B, D, and F), multiple (B), or structurally
abnormal (arrowheads in D and F). Nuclei are
stained light blue with hematoxylin. Inset in D shows
higher magnification of an elongated centrosome.
Note that the nucleus and cell in B are considerably
larger than those in adjacent normal epithelial
cells (A).
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on cell lines (2, 6). Rather, we defined tumors with likely aneuploidy/CIN
as those in which the fraction of nuclei with more than two signals
exceeded 20% (33) and used this measurement as an index of chromosome
instability/aneuploidy. Cells with only one chromosome were recorded and
discussed separately. CIN and centrosome defects were also recorded in
cell lines derived from normal prostate and in situ carcinoma of the prostate
(34).
RESULTS
Centrosome Defects Are Present in Pre-invasive Cancerous
Lesions. Using antibodies to the centrosome protein pericentrin (35),
we examined centrosomes in carcinoma in situ of the uterine cervix
(CIC), female breast (DCIS), and prostate (PIN) as described (2, 21).
Several distinct centrosome abnormalities were detected in these
lesions, including supernumerary centrosomes (Fig. 1B, arrowheads),
abnormally shaped centrosomes, such as elongated or corkscrew
forms (Fig. 1, D and F), and centrosomes of larger diameter than those
in normal epithelium within the same tissue section (Fig. 1, B and D).
Thirty to 72% of all precancerous lesions had abnormal centrosomes
(Fig. 2, A–C), whereas such abnormalities were rarely, if ever, de-
tected in nontumor cells (Fig. 2, A–C). Centrosome defects were more
prevalent in DCIS and CIC than in PIN lesions. This difference was
consistent with differences in histological, cytological, and genetic
features of these lesions, e.g., DCIS and CIC show a high degree of
nuclear atypia, cytologic disarray, loss of cell polarity, and genetic
instability. In fact, on cytologic features alone, they are often indis-
tinguishable from invasive breast and cervical cancers (36, 37). In
contrast, PIN lesions show remarkable preservation of cell polarity
and glandular architecture and can only be distinguished from normal
glands by subtle changes in nuclear and nucleolar features. Similar
levels of centrosome defects in pre-invasive lesions were identified
using antibodies to -tubulin, another core protein of the centrosome
(data not shown).
The Incidence of Centrosome Defects Increases with Higher
Histological Grade of in situ Carcinomas. In situ carcinomas of
different histological/cytologic grade differ in their associated risk of
progression to invasive carcinoma (36, 38, 39). We observed a higher
incidence of centrosome defects in the higher grades of all three
precancerous lesions (Fig. 3). The increase in centrosome abnormal-
ities was greater in the lesions associated with a higher propensity to
evolve into invasive carcinoma and is consistent with a model where
centrosomes contribute to the cytologic and genetic changes that
occur during progression of precancerous lesions.
Mitotic Spindle Abnormalities Are Frequent in Carcinoma in
Situ. One expected consequence of supernumerary centrosomes in
mitotic cells was the development of multipolar mitotic spindles (2,
27). To identify abnormal spindles, we stained sections with -tubu-
lin, which provided the best marker for spindle poles in our immu-
nohistochemical procedure (Fig. 4; see “Materials and Methods”).
The total number of mitotic figures was generally low. The percentage
of samples that contained spindles was 74 (29 of 39, CIC), 35 (12 of
34, DCIS), and 0% (0 of 42, PIN). The low incidence of spindles in
PIN lesions is likely the result of delayed fixation of these tissues and
the relatively slow growth of prostate tumor cells compared with the
other in situ lesions. Of the tumors with spindles, 75% (9 of 12) of
DCIS and 34% (10 of 29) of CIC had at least one abnormal spindle
(Fig. 4, H and G). Defective spindles included multipolar spindles
(three or more poles; Fig. 4, B, D, and F), multiple bipolar spindles in
single cells (Fig. 4E), and asymmetric bipolar and multipolar spindles
(Fig. 4, D and F). In lesions with 10 spindles, a number chosen to
avoid the inherent bias introduced in data by low spindle counts, the
average number of multipolar spindles was 10–16% (Fig. 4I). Mo-
nopolar spindles were also detected, but they could not be authenti-
cated because of the compounding effect of truncation artifacts in-
duced by tissue sectioning. Mitotic figures were infrequently observed
in normal epithelium adjacent to in situ lesions, a likely consequence
of the low mitotic rate of these tissues. When present, these spindles
were normal (symmetric, bipolar, n  4, data not shown). The
Fig. 2. Centrosome defects are prevalent in carcinoma in situ. Centrosome defects are
present in 62, 75, and 28% of CIC (A), DCIS (B), and PIN (C) lesions, respectively (N,
normal epithelia). First column (A–C), cumulative defects; second column (A–C),
breakdown of centrosome defects by category (#, number; Sz, size; Sh, shape).
Fig. 3. The incidence of centrosome defects increases with increasing histological
grade. The cumulative incidence of centrosome defects in each pre-invasive lesion (left
column) includes grades 1–3 for CIC (A, 1–3) and low (L) and high (H) grades for DCIS
(E) and PIN (I). N, normal epithelium. Each subcategory of centrosome defects increases
with grade, including increased centrosome number (B, F, and J), shape abnormalities (C,
G, and K), and size (D, H, and L).
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absence of spindle abnormalities in normal tissues was consistent with
our previous results in nontumor tissues (5, 20) and was confirmed in
another epithelial tissue with a high proliferative rate. In samples of
celiac sprue, a form of intestinal malabsorption in which the intestinal
epithelium has increased mitotic activity caused by increased rates of
mucosal regeneration, we never observed abnormal mitoses (n  45).
Taken together, these data indicated that spindle defects were specific
for in situ lesions.
Centrosome Defects Correlate with CIN in Precancerous Le-
sions. Both chromosome instability (2, 6, 16) and centrosome defects
are common features of epithelial cancers (11, 16, 21, 31). We have
demonstrated previously a correlation between the extent of centro-
some defects and CIN in invasive prostate cancer (2, 21). To deter-
mine whether a correlation exists between centrosome defects and
CIN in carcinoma in situ, we examined consecutive serial tissue
sections for these anomalies (2, 21). Although CIN was observed in
many in situ lesions, it was never seen in normal epithelium in the
same tissue section (Fig. 5, A, C, and E). Moreover, in all three in situ
carcinomas, there was a statistically significant nonrandom associa-
tion (Fisher’s exact test, P  0.005) between centrosome defects and
CIN (Fig. 5, G–I). In fact, most lesions with centrosome defects
showed CIN (63–71%; Fig. 5). Conversely, the fraction of cases that
lacked centrosome defects lacked CIN (81–95%; Fig. 5). The corre-
lation between centrosome defects and CIN was significant despite
the vastly different degrees of centrosome defects between DCIS,
CIC, and PIN (Fig. 2). Interestingly, there were more lesions that had
centrosome defects and lacked CIN (30%) than lesions with CIN
that lacked centrosome defects (10–20%), consistent with a model
where centrosome defects precede CIN in the progression of the
tumor-like phenotype in precancerous lesions (2, 9). Comparison of
the fraction of cells with one chromosome signal (hypoploids) across
all three precancers showed that carcinoma in situ invariably con-
tained fewer cells with one chromosome signal than control tissues
(DCIS, 28.9 / 12 versus control, 38.1 / 10, P  0.023; CIC,
31.2 / 12 versus control 41.3 / 9, P  0.0023; and PIN,
24.6/ 13 versus control 31.2 / 10, P  0.03). In conclusion, in
situ lesions have a lower frequency of single chromosome copy
number and a higher frequency of multiple chromosome copy num-
ber, suggesting that cells in these early lesions are mostly polyploid
and almost never hypoploid.
DISCUSSION
Our results demonstrate that centrosome defects are present in a
significant fraction of in situ carcinomas of the breast, cervix, and
prostate. These results extend our previous observations that centro-
some defects are present in low-grade tumors and increase in more
aggressive carcinomas (21). They also expand on other studies show-
ing centrosome defects in a limited number of in situ lesions from
human breast and rat tissues (20, 29). Because p53 mutations are not
universal in these pre-invasive lesions (see below), we conclude that
abrogation of p53 function is not a prerequisite for the development of
centrosome defects early in tumor development. These observations
are consistent with a role for centrosome defects in the establishment
of carcinoma and perhaps the progression of early lesions to more
aggressive cancers.
Centrosome defects occur frequently in advanced forms of some of
the most common human cancers and may contribute to genetic
instability by impairing the fidelity of chromosome segregation during
mitosis (1, 3, 8, 9, 11, 16). It is currently held that carcinoma in situ
is the immediate precursor of invasive epithelial cancers and that it
shares some but not all genotypic and phenotypic characteristics of
Fig. 4. Mitotic spindle defects are common in
CIC and DCIS. Examples of bipolar mitotic spin-
dles immunostained with -tubulin in CIC and
DCIS (A and C, respectively). Examples of multi-
polar spindles (B, CIC, D, F, and DCIS) and mul-
tiple spindles (E and DCIS). Quantitative analysis
of the number of bipolar (X axis) and multipolar (Y
axis) spindles in each CIC (G) and DCIS lesion
(H). Each circle represents a single lesion. Filled
circles represent lesions with 10 mitoses and
were included in the estimation of the extent of
mitotic spindle defects in CIC and DCIS. On aver-
age, 10 and 17% of the spindles, in CIC and DCIS
lesions with 10 immunostained spindles (red cir-
cles in G and H), are abnormal.
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invasive cancer (38, 40, 41). Our results show that centrosome defects
are present at the earliest morphologically recognizable stages of
tumor development in some of the most common human cancers.
They provide a mechanistic explanation for the commonly observed
CIN and aneuploidy observed in most lesions found in human carci-
noma in situ and experimental models of carcinogenesis (33, 42–45).
These data are consistent with a role for centrosome defects in the
generation of genetic instability during the early stages of the tumor-
igenic process.
Our study also demonstrates that centrosome defects correlate with
the histological/cytologic grade of the in situ lesion and thus support
a role for the centrosome in the induction of the morphological
phenotype characteristic of carcinoma in situ. Centrosomes have been
shown to play a role in cell polarity (46), shape (47, 48), and motility
(47), all of which are perturbed in all in situ cancers examined in this
study. Moreover, the presence of mitotic spindle defects in many CIC
and DCIS lesions and the cosegregation of centrosome abnormalities
with CIN strongly suggest that centrosome defects have a functional
impact in in situ carcinoma.
Our results are consistent with a role for centrosome defects in the
development of aggressive tumors, rather than those that remain
benign. This idea is supported by the high prevalence of centrosome
abnormalities in lesions with a high rate of progression to high-grade
cancer (DCIS and CIC) and the low prevalence of centrosome defects
in PIN lesions, the majority of which progresses to low-grade invasive
cancers. Because DCIS and CIC are usually indistinguishable cyto-
logically from aggressive cancers (36, 49), it is believed that they give
rise to these aggressive cancers. In contrast, cancers of the prostate are
usually low grade (50), consistent with the low-grade appearance of
most PIN lesions. These results support our centrosome-mediated
model of tumor genesis (2), where centrosome defects induce dra-
matic and persistent changes in chromosome number (CIN), thereby
shuffling the genome and allowing selection of the most aggressive
phenotypes, such as those seen in invasive cancers.
The presence of centrosome abnormalities at the earliest stages of
disease may also have the potential to predict evolution of in situ
lesions into high-grade invasive cancers. This is of particular interest
for the management of prostate cancer, because the majority of these
tumors are biologically low grade but with time may progress to
aggressive form. Currently, these cancers are often treated by prosta-
tectomy, because there is no effective prognostic indicator of aggres-
sive disease. If centrosome abnormalities can predict development to
Fig. 5. Centrosome abnormalities correlate with
chromosome instability in carcinoma in situ. Exam-
ples of in situ hybridization reactions performed on
samples of CIC (B), DCIS (D), and PIN (F) are
shown. Many cells have more than two signals for
chromosome #8 (arrowheads in B, D, and F) and
thus exhibit chromosome instability (CIN). Cells
in adjacent normal epithelium (A, C, and E) rarely
have more than two signals. Quantitative analysis of
CIN in CIC (G), DCIS (H), and PIN (I) lesions
with normal centrosomes (N) or abnormal centro-
somes (A). CIN is present in most lesions with
abnormal centrosomes and a small fraction of le-
sions lacking centrosome abnormalities.
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high-grade cancer, they would provide a sorely needed surrogate
marker for aggressive disease. We are currently testing if centrosome
defects correlate with aggressive prostate cancer by examining PIN
lesions from patients that subsequently progress to invasive cancer.
On the basis of our previous work showing that the incidence of
centrosome defects are higher in more aggressive tumors (21), we are
hopeful that their incidence will also be higher in precancerous lesions
that subsequently progress to aggressive tumors.
An interesting observation made in this study was the presence of
low, yet measurable levels of centrosome defects in morphologically
normal epithelium adjacent to CIC lesions (Fig. 2A). We speculate
that this may be attributable to the presence of human papilloma virus
infection. It is well established that papilloma virus is the cause of
nearly all carcinomas of the cervix and present in all precursor lesions
(51). Moreover, it has been demonstrated recently that papilloma virus
can rapidly induce centrosome abnormalities in squamous epithelial
cells in vitro (52).
Our observations also suggest a mechanism for centrosome-medi-
ated generation of genetic instability in carcinoma in situ. The excel-
lent correlation between centrosome defects, aberrant spindles, and
CIN indicates that abnormal centrosomes contribute to spindle disor-
ganization, chromosome missegregation, and genetic instability in
these lesions. These data also suggest that supernumerary centrosomes
lead to multipolar spindles and do not merely coalesce to form bipolar
spindles as it has been suggested from work in cell lines (8, 53).
Although our study answers the important question of whether
centrosome defects occur in pre-invasive cancers, it also leaves a
number of interesting issues unanswered. One of the most important
issues is whether centrosome defects are a cause or consequence of
the in situ carcinoma phenotype. This is an issue of overriding
importance in that the identification of the mechanism by which
centrosome abnormalities arise may lead to both predictive testing and
cancer-specific therapeutic interventions. There are many ways in
which centrosome defects can arise. These include changes in proteins
involved in cell cycle control, centrosome structure or function, and
DNA repair, e.g., mutation or elimination of p53 (54–56) or p53
downstream effectors/regulators, such as Mdm2 (57), p21Waf/Cip1 (54,
57, 58), and GADD45 (44, 59), induces centrosome abnormalities.
Abrogation of postmitotic p53-dependent checkpoints may be critical
in allowing tetraploid cells with supernumerary centrosomes to con-
tinue to cycle (60–64). Similarly, alteration in the levels of centro-
some-associated proteins, such as pericentrin (21, 27), -tubulin (65),
aurora (24, 25, 28), polo (66), TACC (67), and RanBP (68), leads to
abnormal centrosomes. Moreover, mutation or functional abrogation
of proteins involved in DNA repair, such as Xrcc3 (69), Xrcc2 (69),
BRCA1 (70, 71), BRCA2 (70, 72, 73), Mre11 (74), DNA polymerase
 (75), or genome damage-signaling proteins such as ATR (76), can
also lead to centrosome abnormalities. Lastly, centrosome abnormal-
ities can arise by mutation of the adenomatous polyposis coli gene
whose product interacts with microtubules (77), by cytokinesis failure
(24), and by ectopic assembly of centrosome components into acen-
triolar microtubule-organizing centers (9, 21, 27).
We do not know which of these mechanisms is responsible for
inducing centrosome defects in carcinoma in situ or if another as yet
unidentified mechanism/pathway is involved. We believe it is unlikely
that p53 mutations can account for our findings: (a) p53 mutations are
not common in DCIS (78) and PIN (79); (b) centrosome defects in
carcinoma in situ are not only numerical but also structural; (c) human
somatic cells rendered p53/ by targeted homologous recombina-
tion do not develop CIN or centrosome abnormalities unless chal-
lenged (80); (d) overexpression of endogenous p53, which correlates
highly with mutated p53, occurred in 20% of CIC and PIN lesions
(data not shown); and (e) supernumerary centrosomes in p53/ or
p53 mutant cells (54, 55) may be secondary to the combined effects
of cytokinesis failure and abrogation of postmitotic checkpoints, thus
allowing polyploid cells to reenter the cell cycle and undergo mitosis
with supernumerary centrosomes (24). Under these conditions, cells
with supernumerary centrosomes have the potential to perpetuate
chromosome instability by missegregating chromosomes through
multipolar mitoses.
In conclusion, we have shown that centrosome defects are present
in a significant percentage of pre-invasive carcinomas and that they
occur together with mitotic spindle defects and chromosome instabil-
ity. We propose that centrosomes may contribute directly to chromo-
some missegregation and genetic instability and, through this process,
accelerate the accumulation of genes with oncogenic mutations and
loss of genes encoding tumor suppressors, as characteristically ob-
served in human carcinoma.
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